Skip to the search field
Skip to the main page content
Skip to the Accessibility Statement
Research.fi
Menu
Suomeksi
På svenska
In English
Home
Search
Science and Innovation Policy
Science and research news
In English
- 23 results
Publications -
23
search results
Skip to search results
Show as image
Filter results
Displaying results 1 - 10 / 23
10
50
100
results / page
What
publication
information is included in the service?
Icon
Publication name
Authors
Publication channel
Year
Publications information icon
Crossover and rechallenge with
pembrolizumab
in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma
Peer-reviewed
Open access
DOI
10.1016/j.ejca.2021.09.023
Eggermont, Alexander MM; Meshcheryakov, Andrey; Atkinson, Victoria; Blank, Christian U.; Mandala, Ma...
European journal of cancer
2021
Publications information icon
Adjuvant
Pembrolizumab
after Nephrectomy in Renal-Cell Carcinoma
Peer-reviewed
Choueiri TK; Tomczak P; Park SH; Venugopal B; Ferguson T; Chang YH; Hajek J; Symeonides SN; Lee JL; ...
New England Journal of Medicine
2021
Publications information icon
Pembrolizumab
plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
Peer-reviewed
Open access
DOI
10.1056/NEJMoa1801005
KEYNOTE-189 Investigators; Gandhi, L.; Rodriguez-Abreu, D.; Gadgeel, S.; Esteban, E.; Felip, E.; De ...
The new england journal of medicine
2018
Publications information icon
Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With
Pembrolizumab
in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma
Peer-reviewed
Open access
DOI
10.1001/jamaoncol.2019.1048
Konstantinopoulos, Panagiotis A.; Waggoner, Steven; Vidal, Gregory A.; Mita, Monica; Moroney, John W...
JAMA oncology
2019
Publications information icon
Pembrolizumab
versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Peer-reviewed
Powles T; Tomczak P; Park SH; Venugopal B; Ferguson T; Symeonides SN; Hajek J; Gurney H; Chang YH; L...
Lancet Oncology
2022
Publications information icon
Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer
Peer-reviewed
Open access
DOI
10.1038/s41467-020-15315-8
Färkkilä, Anniina; Gulhan, Doga C.; Casado, Julia; Jacobson, Connor A.; Nguyen, Huy; Kochupurakkal, ...
Nature communications
2020
Publications information icon
Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy Three-Year Follow-up of a Randomized Phase 3 Trial
Peer-reviewed
Open access
DOI
10.1001/jamaoncol.2018.4514
Ascierto, Paolo A.; Long, Georgina V.; Robert, Caroline; Brady, Benjamin; Dutriaux, Caroline; Di Gia...
JAMA oncology
2019
Publications information icon
Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma
Peer-reviewed
Open access
DOI
10.1200/JCO.20.00995
Robert, Caroline; Long, Georgina V.; Brady, Benjamin; Dutriaux, Caroline; Di Giacomo, Anna Maria; Mo...
Journal of clinical oncology
2020
Publications information icon
Selective drug combination vulnerabilities in STAT3- and TP53-mutant malignant NK cells
Peer-reviewed
Open access
DOI
10.1182/bloodadvances.2020003300
Parri, E; Kuusanmaki, H; Bulanova, D; Mustjoki, S; Wennerberg, K
Blood advances
2021
Publications information icon
Genome-scale screens identify factors regulating tumor cell responses to natural killer cells
Peer-reviewed
DOI
10.1038/s41588-021-00889-w
Sheffer, Michal; Lowry, Emily; Beelen, Nicky; Borah, Minasri; Naffar-Abu Amara, Suha; Mader, Chris C...
Nature genetics
2021
Crossover and rechallenge with
pembrolizumab
in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma
Peer-reviewed
Open access
DOI
10.1016/j.ejca.2021.09.023
2021
Adjuvant
Pembrolizumab
after Nephrectomy in Renal-Cell Carcinoma
Peer-reviewed
2021
Pembrolizumab
plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
Peer-reviewed
Open access
DOI
10.1056/NEJMoa1801005
2018
Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With
Pembrolizumab
in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma
Peer-reviewed
Open access
DOI
10.1001/jamaoncol.2019.1048
2019
Pembrolizumab
versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Peer-reviewed
2022
Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer
Peer-reviewed
Open access
DOI
10.1038/s41467-020-15315-8
2020
Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy Three-Year Follow-up of a Randomized Phase 3 Trial
Peer-reviewed
Open access
DOI
10.1001/jamaoncol.2018.4514
2019
Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma
Peer-reviewed
Open access
DOI
10.1200/JCO.20.00995
2020
Selective drug combination vulnerabilities in STAT3- and TP53-mutant malignant NK cells
Peer-reviewed
Open access
DOI
10.1182/bloodadvances.2020003300
2021
Genome-scale screens identify factors regulating tumor cell responses to natural killer cells
Peer-reviewed
DOI
10.1038/s41588-021-00889-w
2021
Previous
1
2
3
Next
Displaying results 1 - 10 / 23
Page 1
Sort